miRNAs: micro-managers of anticancer combination therapies

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Angiogenesis is one of the hallmarks of cancer progression and as such has been considered a target of therapeutic interest. However, single targeted agents have not fully lived up to the initial promise of anti-angiogenic therapy. Therefore, it has been suggested that combining therapies and agents will be the way forward in the oncology field. In recent years, microRNAs (miRNAs) have received considerable attention as drivers of tumor development and progression, either acting as tumor suppressors or as oncogenes (so-called oncomiRs), as well as in the process of tumor angiogenesis (angiomiRs). Not only from a functional, but also from a therapeutic view, miRNAs are attractive tools. Thus far, several mimics and antagonists of miRNAs have entered clinical development. Here, we review the provenance and promise of miRNAs as targets as well as therapeutics to contribute to anti-angiogenesis-based (combination) treatment of cancer.

Original languageEnglish
Pages (from-to)269-285
Number of pages17
JournalAngiogenesis
Volume20
Issue number2
DOIs
Publication statusPublished - May 2017

Cite this

@article{012e51149bba4986a2b8d3f750546c32,
title = "miRNAs: micro-managers of anticancer combination therapies",
abstract = "Angiogenesis is one of the hallmarks of cancer progression and as such has been considered a target of therapeutic interest. However, single targeted agents have not fully lived up to the initial promise of anti-angiogenic therapy. Therefore, it has been suggested that combining therapies and agents will be the way forward in the oncology field. In recent years, microRNAs (miRNAs) have received considerable attention as drivers of tumor development and progression, either acting as tumor suppressors or as oncogenes (so-called oncomiRs), as well as in the process of tumor angiogenesis (angiomiRs). Not only from a functional, but also from a therapeutic view, miRNAs are attractive tools. Thus far, several mimics and antagonists of miRNAs have entered clinical development. Here, we review the provenance and promise of miRNAs as targets as well as therapeutics to contribute to anti-angiogenesis-based (combination) treatment of cancer.",
keywords = "Animals, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Humans, MicroRNAs/metabolism, Neoplasms/blood supply, Neovascularization, Pathologic/drug therapy, RNA, Neoplasm/metabolism",
author = "{van Beijnum}, {Judy R} and Elisa Giovannetti and Dennis Poel and Patrycja Nowak-Sliwinska and Griffioen, {Arjan W}",
year = "2017",
month = "5",
doi = "10.1007/s10456-017-9545-x",
language = "English",
volume = "20",
pages = "269--285",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer Netherlands",
number = "2",

}

miRNAs : micro-managers of anticancer combination therapies. / van Beijnum, Judy R; Giovannetti, Elisa; Poel, Dennis; Nowak-Sliwinska, Patrycja; Griffioen, Arjan W.

In: Angiogenesis, Vol. 20, No. 2, 05.2017, p. 269-285.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - miRNAs

T2 - micro-managers of anticancer combination therapies

AU - van Beijnum, Judy R

AU - Giovannetti, Elisa

AU - Poel, Dennis

AU - Nowak-Sliwinska, Patrycja

AU - Griffioen, Arjan W

PY - 2017/5

Y1 - 2017/5

N2 - Angiogenesis is one of the hallmarks of cancer progression and as such has been considered a target of therapeutic interest. However, single targeted agents have not fully lived up to the initial promise of anti-angiogenic therapy. Therefore, it has been suggested that combining therapies and agents will be the way forward in the oncology field. In recent years, microRNAs (miRNAs) have received considerable attention as drivers of tumor development and progression, either acting as tumor suppressors or as oncogenes (so-called oncomiRs), as well as in the process of tumor angiogenesis (angiomiRs). Not only from a functional, but also from a therapeutic view, miRNAs are attractive tools. Thus far, several mimics and antagonists of miRNAs have entered clinical development. Here, we review the provenance and promise of miRNAs as targets as well as therapeutics to contribute to anti-angiogenesis-based (combination) treatment of cancer.

AB - Angiogenesis is one of the hallmarks of cancer progression and as such has been considered a target of therapeutic interest. However, single targeted agents have not fully lived up to the initial promise of anti-angiogenic therapy. Therefore, it has been suggested that combining therapies and agents will be the way forward in the oncology field. In recent years, microRNAs (miRNAs) have received considerable attention as drivers of tumor development and progression, either acting as tumor suppressors or as oncogenes (so-called oncomiRs), as well as in the process of tumor angiogenesis (angiomiRs). Not only from a functional, but also from a therapeutic view, miRNAs are attractive tools. Thus far, several mimics and antagonists of miRNAs have entered clinical development. Here, we review the provenance and promise of miRNAs as targets as well as therapeutics to contribute to anti-angiogenesis-based (combination) treatment of cancer.

KW - Animals

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Humans

KW - MicroRNAs/metabolism

KW - Neoplasms/blood supply

KW - Neovascularization, Pathologic/drug therapy

KW - RNA, Neoplasm/metabolism

U2 - 10.1007/s10456-017-9545-x

DO - 10.1007/s10456-017-9545-x

M3 - Review article

VL - 20

SP - 269

EP - 285

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 2

ER -